Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

A vaccine causes the immune system to produce antibodies (immune response) to specific germs to protect the patient. This study evaluates the immune response to the pneumococcal vaccine in adults with Alefacept-treated chronic plaque psoriasis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Alefacept; Heptavalent Pneumococcal Conjugate Vaccine; Vaccines

Criteria

Inclusion Criteria:

• Subject has chronic plaque psoriasis

• Subject has at least 5% body surface area affected with psoriasis

Exclusion Criteria:

• Skin disorder other than plaque psoriasis in affected area

• Previously immunized with any pneumococcal vaccine

• Subject has pustular or erythrodermic psoriasis

• Subject is immunocompromised

• Six or more herpes simplex virus outbreaks per year

• History or malignancy, chronic serious infection or hepatic disease